All sounds fabulous - Management have always been pretty special. What I am slightly unsure about is the last line -
Neuren has an obligation not to develop .... any product ..... for North America in an indication for which Acadia develops trofinitide, except for Phelan-McDermind, Pitt Hopkins, Angelman and Prader Willis syndromes.
A number of years ago (and I am sure it remains the case) it was suggested Trof / 2591 may help a whole range of 'indications'- Autism / MS / TBI .. maybe even Parkinsons (from memory).
Sounds like Acadia can develop for one (or a number) of these and Neuren would thus be excluded. Cannot imagine Acadia could afford to seriously develop too many indications at once, but would like to know how this is designed operate. Dare say the fine print will be all-important, but would like to hear more at some stage.
All the best to investors and potential users.
All sounds fabulous - Management have always been pretty...
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B | |||
| Open | High | Low | Value | Volume |
| $19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $19.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.00 | 3262 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |